antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2023-68-9-10-85-92antibiotics-1083Research ArticleОБЗОРЫREVIEWSКардиотоксичные лекарственные средства при лечении COVID-19Cardiotoxic Drugs Used in the Treatment of COVID-19https://orcid.org/0000-0002-6665-8601ЗмитрукевичА. С.ZmitrukevichA. S.

Змитрукевич Андрей Станиславович — врач общей практики; ассистент кафедры пропедевтики внутренних болезней

ул. Кравченко, д.14, Городская поликлиника № 11, г. Москва, 119331

Andrei S. Zmitrukevich — General practitioner; Assistant of the Department of Propaedeutics of Internal Diseases of the Faculty of General Medicine

 14 Kravchenko str., Moscow, 119331

andrey1881889@gmail.comhttps://orcid.org/0000-0001-9183-3216МамедоваА. Е.MamedovaA. E.

Мамедова Анастасия Евгеньевна – ассистент кафедры Биологической химии

Гродно

Anastasiya E. Mamedova — Assistant at the Department of Biological Chemistry

Grodno

ГБУЗ города Москвы «Городская поликлиника № 11 ДЗМ»; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» МЗ РФРоссияCity Clinic No. 11 of the Moscow Healthcare Department; Pirogov Russian National Research Medical UniversityRussian FederationУчреждение образования «Гродненский государственный медицинский университет»БеларусьGrodno State Medical UniversityBelarus202316012024689-108592Copyright © Змитрукевич А.С., Мамедова А.Е., 20242024Змитрукевич А.С., Мамедова А.Е.Zmitrukevich A.S., Mamedova A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1083Актуальность

Актуальность. Пандемия COVID-19 вызвана вирусом SARS-CoV-2. Кардиотоксичному потенциалу лекарственных средств, используемых при лечении COVID-19, уделяется недостаточное внимание.

Цель

Цель. Краткий отчёт о влиянии на сердечно-сосудистую систему организма наиболее распространённых препаратов при лечении COVID-19.

Обсуждение

Обсуждение. Для лечения заболевания COVID-19 использовались разные лекарственные средства. Среди наиболее распространённых препаратов стоит выделить гидроксихлорохин, ремдесивир, фавипиравир, фторхинолоны, интерферон-α2b, глюкокортикоиды, молнупиравир и ритонавир/нирматрелвир. Большинство препаратов способны вызывать изменения со стороны сердечно-сосудистой системы, особенно изменение интервала QT.

Заключение

Заключение. Врачи должны учитывать кардиотоксичный потенциал всех лекарственных средств, используемых при лечении COVID-19. Терапевты и врачи общей практики должны знать о сердечно-сосудистых рисках при ведении пациентов с COVID-19, а также диспансеризации населения.

Background

Background. The COVID-19 pandemic is caused by the SARS-CoV-2 virus. Insufficient attention is paid to the cardiotoxic potential of the drugs used in the treatment of COVID-19.

Aim

Aim. A brief report on the effect of the drugs commonly used in the treatment of COVID-19 on the cardiovascular system.

Discussion

Discussion. Various medications have been used to treat COVID-19. Some of the most common drugs include hydroxychloroquine, remdesvir, favipiravir, fluoroquinolones, interferon-α2b, glucocorticoids, molnupiravir, and ritonavir/nirmatrelvir. Most medications can cause changes in the cardiovascular system, especially in the QT interval.

Conclusions

Conclusions. Physicians should take into account the cardiotoxic potential of all medications used in the treatment of COVID-19. Therapists and general practitioners should be aware of cardiovascular risks in the management of patients with COVID-19, as well as the prophylactic medical examinations of the population.

COVID-19гидроксихлорохинглюкокортикоидыинтерферонремдесивирфавипиравирфторхинолоныCOVID-19glucocorticoidshydroxychloroquineinterferonremdesivirfavipiravirfluoroquinolonesReferencesJi W., Wang W., Zhao X. et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020; 92 (4): 433–440. doi: 10.1002/jmv.25682.Ji W., Wang W., Zhao X. et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020; 92 (4): 433–440. doi: 10.1002/jmv.25682.Zmitrukevich A.S. Cardiovascular сhanges in COVID19. Acta Scientific Medical Sciences. 2022; 6 (Special Issue 2): 32–39. doi: https://doi.org/10.31080/ASMS.2022.S02.0007.Zmitrukevich A.S. Cardiovascular сhanges in COVID19. Acta Scientific Medical Sciences. 2022; 6 (Special Issue 2): 32–39. doi: https://doi.org/10.31080/ASMS.2022.S02.0007.Elming H., Brendorp B., Køber L. et al. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev. 2002; 6 (3): 289–294. doi: 10.1023/A:1016345412555.Elming H., Brendorp B., Køber L. et al. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev. 2002; 6 (3): 289–294. doi: 10.1023/A:1016345412555.Romanelli F., Smith K.M., Hoven A.D. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharmaceutical Des. 2004; 10 (21): 2643–2648. doi: 10.2174/1381612043383791.Romanelli F., Smith K.M., Hoven A.D. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharmaceutical Des. 2004; 10 (21): 2643–2648. doi: 10.2174/1381612043383791.Ooi E.E., Chew J.S., Loh J.P., Chua R. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006; 3 (1): 1–3. doi: 10.1186/1743-422X-3-39.Ooi E.E., Chew J.S., Loh J.P., Chua R. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006; 3 (1): 1–3. doi: 10.1186/1743-422X-3-39.Vincent M.J., Bergeron E., Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2 (1): 1–0. doi: 10.1186/1743-422X-2-69.Vincent M.J., Bergeron E., Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005; 2 (1): 1–0. doi: 10.1186/1743-422X-2-69.Yao X., Ye F., Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (15): 732–739. doi: 10.1093/cid/ciaa237.Yao X., Ye F., Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71 (15): 732–739. doi: 10.1093/cid/ciaa237.Giudicessi J.R., Noseworthy P.A., Friedman P.A., Ackerman M.J. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020; 95 (6): 1213–1221. doi: 10.1016/j.mayocp.2020.03.024.Giudicessi J.R., Noseworthy P.A., Friedman P.A., Ackerman M.J. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020; 95 (6): 1213–1221. doi: 10.1016/j.mayocp.2020.03.024.Schrezenmeier E., Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16 (3): 155–166. doi: 10.1038/s41584-020-0372-x.Schrezenmeier E., Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020; 16 (3): 155–166. doi: 10.1038/s41584-020-0372-x.Pani A., Lauriola M., Romandini A., Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrobial Agents. 2020; 56 (2): 106053. doi: 10.1016/j.ijantimicag.2020.106053.Pani A., Lauriola M., Romandini A., Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrobial Agents. 2020; 56 (2): 106053. doi: 10.1016/j.ijantimicag.2020.106053.Tönnesmann E., Kandolf R., Lewalter T. Chloroquine cardiomyopathy — a review of the literature. Immunopharmacol Immunotoxicol. 2013; 35 (3): 434–442. doi: 10.3109/08923973.2013.780078.Tönnesmann E., Kandolf R., Lewalter T. Chloroquine cardiomyopathy — a review of the literature. Immunopharmacol Immunotoxicol. 2013; 35 (3): 434–442. doi: 10.3109/08923973.2013.780078.Radke J.B., Kingery J.M., Maakestad J., Krasowski M.D. Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: a case report. Toxicol Rep. 2019; 6: 1040–1046. doi: 10.1016/j.toxrep.2019.10.006.Radke J.B., Kingery J.M., Maakestad J., Krasowski M.D. Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: a case report. Toxicol Rep. 2019; 6: 1040–1046. doi: 10.1016/j.toxrep.2019.10.006.Chatre C., Roubille F., Vernhet H. et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018; 41 (10): 919–931. doi: 10.1007/s40264-018-0689-4.Chatre C., Roubille F., Vernhet H. et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018; 41 (10): 919–931. doi: 10.1007/s40264-018-0689-4.Hsia B.C., Greige N., Quiroz J.A. et al. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. J Interv Card Electrophysiol. 2020; 59 (2): 337–345. doi: 10.1007/s10840-020-00822-x.Hsia B.C., Greige N., Quiroz J.A. et al. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. J Interv Card Electrophysiol. 2020; 59 (2): 337–345. doi: 10.1007/s10840-020-00822-x.Gautret P., Lagier J.C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrobial Agents. 2020; 56 (1): 105949. doi: 10.1016/j.ijantimicag.2020.105949.Gautret P., Lagier J.C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrobial Agents. 2020; 56 (1): 105949. doi: 10.1016/j.ijantimicag.2020.105949.Shah R.R. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021; 46 (1): 17–27. doi: 10.1111/jcpt.13267.Shah R.R. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021; 46 (1): 17–27. doi: 10.1111/jcpt.13267.Richter S., Parolin C., Palumbo M., Palù G. Antiviral properties of quinolone-based drugs. Curr Drug Targets-Infect Dis. 2004; 4 (2): 111–116. doi: 10.2174/1568005043340920.Richter S., Parolin C., Palumbo M., Palù G. Antiviral properties of quinolone-based drugs. Curr Drug Targets-Infect Dis. 2004; 4 (2): 111–116. doi: 10.2174/1568005043340920.Cui Q., Cheng H., Xiong R. et al. Identification of diaryl-quinoline compounds as entry inhibitors of Ebola virus. Viruses. 2018; 10 (12): 678. doi: 10.3390/v10120678.Cui Q., Cheng H., Xiong R. et al. Identification of diaryl-quinoline compounds as entry inhibitors of Ebola virus. Viruses. 2018; 10 (12): 678. doi: 10.3390/v10120678.Khan I.A., Siddiqui S., Rehmani S. et al. Fluoroquinolones inhibit HCV by targeting its helicase. Antiviral Ther. 2012; 17 (3): 467–476. doi: 10.3851/IMP1937.Khan I.A., Siddiqui S., Rehmani S. et al. Fluoroquinolones inhibit HCV by targeting its helicase. Antiviral Ther. 2012; 17 (3): 467–476. doi: 10.3851/IMP1937.Enoki Y., Ishima Y., Tanaka R. et al. Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury. PloS One. 2015; 10 (6): e0130248. doi: 10.1371/journal.pone.0130248.Enoki Y., Ishima Y., Tanaka R. et al. Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury. PloS One. 2015; 10 (6): e0130248. doi: 10.1371/journal.pone.0130248.Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005; 33 (2): 55–70. doi: 10.1007/s15010-005-8209-8.Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005; 33 (2): 55–70. doi: 10.1007/s15010-005-8209-8.Marciniec K., Beberok A., Pęcak P. et al. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharm Rep. 2020; 72 (6): 1553–1561. doi: 10.1007/s43440-020-00169-0.Marciniec K., Beberok A., Pęcak P. et al. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharm Rep. 2020; 72 (6): 1553–1561. doi: 10.1007/s43440-020-00169-0.Karampela I., Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19?. Arch Med Res. 2020; 51 (7): 741–742. doi: 10.1016/j.arcmed.2020.06.004.Karampela I., Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19?. Arch Med Res. 2020; 51 (7): 741–742. doi: 10.1016/j.arcmed.2020.06.004.Falagas M.E., Rafailidis P.I., Rosmarakis E.S. Arrhythmias associated with fluoroquinolone therapy. International J Antimicrob Agents. 2007; 29 (4): 374–379. doi: 10.1016/j.ijantimicag.2006.11.011.Falagas M.E., Rafailidis P.I., Rosmarakis E.S. Arrhythmias associated with fluoroquinolone therapy. International J Antimicrob Agents. 2007; 29 (4): 374–379. doi: 10.1016/j.ijantimicag.2006.11.011.Yu R., Li P. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021; 458: 152822. doi: 10.1016/j.tox.2021.152822.Yu R., Li P. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021; 458: 152822. doi: 10.1016/j.tox.2021.152822.Siegel D., Hui H.C., Doerffler E. et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine cnucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem. 2017; 60 (5): 1648–1661. doi: 10.1021/acs.jmedchem.6b01594.Siegel D., Hui H.C., Doerffler E. et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine cnucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem. 2017; 60 (5): 1648–1661. doi: 10.1021/acs.jmedchem.6b01594.Choi S.W., Shin J.S., Park S.J. et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020; 184: 104955. doi: 10.1016/j.antiviral.2020.104955.Choi S.W., Shin J.S., Park S.J. et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020; 184: 104955. doi: 10.1016/j.antiviral.2020.104955.Mulangu S., Dodd L.E., Davey Jr R.T. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Eng J Med. 2019; 381 (24): 2293–2303. doi: 10.1056/NEJMoa1910993.Mulangu S., Dodd L.E., Davey Jr R.T. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Eng J Med. 2019; 381 (24): 2293–2303. doi: 10.1056/NEJMoa1910993.Rau C., Apostolidou S., Singer D. et al. Remdesivir, sinus bradycardia and therapeutic drug monitoring in children with severe COVID-19. The Pediatric Infectious Disease Journal. 2021; 40 (12): e528. doi: 10.1097/INF.0000000000003309.Rau C., Apostolidou S., Singer D. et al. Remdesivir, sinus bradycardia and therapeutic drug monitoring in children with severe COVID-19. The Pediatric Infectious Disease Journal. 2021; 40 (12): e528. doi: 10.1097/INF.0000000000003309.Eleftheriou I., Liaska M., Krepis P. et al. Sinus bradycardia in children treated with remdesivir for COVID-19. Pediatr Infect Dis J. 2021; 40 (9): e356. doi: 10.1097/INF.0000000000003214.Eleftheriou I., Liaska M., Krepis P. et al. Sinus bradycardia in children treated with remdesivir for COVID-19. Pediatr Infect Dis J. 2021; 40 (9): e356. doi: 10.1097/INF.0000000000003214.Gupta A.K., Parker B.M., Priyadarshi V., Parker J. Cardiac adverse events with remdesivir in COVID-19 infection. Cureus. 2020; 12 (10). doi: 10.7759/cureus.11132.Gupta A.K., Parker B.M., Priyadarshi V., Parker J. Cardiac adverse events with remdesivir in COVID-19 infection. Cureus. 2020; 12 (10). doi: 10.7759/cureus.11132.Baranovich T., Wong S.S., Armstrong J. et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 2013; 87 (7): 3741–3751. doi: 10.1128/JVI.02346-12.Baranovich T., Wong S.S., Armstrong J. et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 2013; 87 (7): 3741–3751. doi: 10.1128/JVI.02346-12.Shannon A., Selisko B., Le N.T. et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. BioRxiv. 2020 May 15. doi: 10.1101/2020.05.15.098731.Shannon A., Selisko B., Le N.T. et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. BioRxiv. 2020 May 15. doi: 10.1101/2020.05.15.098731.Руженцова Т. А., Чухляев П. В., Хавкина Д. А., и др. Эффективность и безопасность применения фавипиравира в комплексной терапии COVID-19 лёгкого и среднетяжёлого течения. Инфекционные болезни: Новости. Мнения. Обучение. 2020; 9: (4): 26–38. doi: https://doi.org/10.33029/2305-3496-2020-9-4-26-38.Ruzhentsova T.A., Chukhlyaev P.V., Khavkina D.A. Efficacy and safety of favipiravir in mild and moderate COVID-19: results of a randomized trial. Infectious diseases: News, Opinions, Training. 2020; 9 (4): 26–38. doi: https://doi.org/10.33029/2305-3496-2020-9-4-26-38. (in Russian)]Киселёв Ю.Ю., Матвеев А.В., Мирзаев К.Б., Сычёв Д.А. Мониторинг безопасности применения фавипиравира: управление рисками развития нежелательных лекарственных реакций в клинической практике. Качественная клиническая практика. 2020; Спецвыпуск S4: 115–119. doi: https://doi.org/10.37489/2588-0519-2020-S4-115-119.Kiselev Yu.Yu., Matveev A.V., Mirzaev K.B., Sychev D.A. Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020; (4S): 115–119. doi: https://doi.org/10.37489/2588-0519-2020-S4-115-119. (in Russian)]Michaud V., Dow P., Al. Rihani S.B. et al. Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2021; 14 (1): 20–28. doi: 10.1111/cts.12882.Michaud V., Dow P., Al. Rihani S.B. et al. Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2021; 14 (1): 20–28. doi: 10.1111/cts.12882.Chinello P., Petrosillo N., Pittalis S. et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. Pl=LoS Negl Trop Dis. 2017; 11 (12): e0006034. doi: 10.1371/journal.pntd.0006034.Chinello P., Petrosillo N., Pittalis S. et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. Pl=LoS Negl Trop Dis. 2017; 11 (12): e0006034. doi: 10.1371/journal.pntd.0006034.Kopecky-Bromberg S.A., Martínez-Sobrido L., Frieman M. et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007; 81 (2): 548–57. doi: 10.1128/JVI.01782-06.Kopecky-Bromberg S.A., Martínez-Sobrido L., Frieman M. et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007; 81 (2): 548–57. doi: 10.1128/JVI.01782-06.Zhou Q., Chen V., Shannon C.P. et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. doi: 10.3389/fimmu.2020.01061.Zhou Q., Chen V., Shannon C.P. et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020; 11: 1061. doi: 10.3389/fimmu.2020.01061.Wang N., Zhan Y., Zhu L. et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020; 28 (3): 455–464. doi: 10.1016/j.chom.2020.07.005.Wang N., Zhan Y., Zhu L. et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020; 28 (3): 455–464. doi: 10.1016/j.chom.2020.07.005.Логинова С.Я., Щукина В.Н., Савенко С.В., Борисевич С.В. Активность человеческого рекомбинантного интерферона альфа-2b in vitro в отношении вируса SARS-CoV-2. Вопросы Вирусологии. 2021; 66 (2): 123– 128. doi: https://doi.org/10.36233/0507-4088-13.Loginova S.Y., Shсhukina V.N., Savenko S.V., Borisevich S.V. In vitro activity of human recombinant alpha-2b interferon against SARS-CoV-2 virus. Problems of Virology. 2021; 66 (2): 123–128. doi: https://doi.org/10.36233/0507-4088-13. (in Russian)]Li X., Liu T., Hai X., Li L. Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study. Immunopharmacol Immunotoxicol. 2021; 43 (6): 644–650. doi: 10.1080/08923973.2021.1992634.Li X., Liu T., Hai X., Li L. Interferon-α2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study. Immunopharmacol Immunotoxicol. 2021; 43 (6): 644–650. doi: 10.1080/08923973.2021.1992634.Popescu C., Arama V., Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis-case report. BMC Gastroenterol. 2011; 11 (1): 1–4. doi: 10.1186/1471-230X-11-30.Popescu C., Arama V., Gliga S. Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis-case report. BMC Gastroenterol. 2011; 11 (1): 1–4. doi: 10.1186/1471-230X-11-30.Вершинина С. Ф., Гершанович М. Л., Махнова Е. В., и др. Токсическое действие противоопухолевой терапии на сердечно-сосудистую систему. Вопросы онкологии. 2010; 56 (2): 234–239.Vershinina S.F., Gershanovich M.L., Makhnova E.V. et al. Toxic effect of antitumor therapy on the cardiovascular system. Voprosy Onkologii. 2010; 56 (2): 234–239. (in Russian)]Sonnenblick M., Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest. 1991; 99 (3): 557–561. doi: 10.1378/chest.99.3.557.Sonnenblick M., Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest. 1991; 99 (3): 557–561. doi: 10.1378/chest.99.3.557.Rechciński T., Matusik D., Rudziński T. et al. Cardiotoxic properties of interferon. Pol Arch Med Wewn. 2007; 117 (1–2): 49–52.Rechciński T., Matusik D., Rudziński T. et al. Cardiotoxic properties of interferon. Pol Arch Med Wewn. 2007; 117 (1–2): 49–52.Williams D.M. Clinical pharmacology of corticosteroids. Respir Care. 2018; 63 (6): 655–670. doi: 10.4187/respcare.06314.Williams D.M. Clinical pharmacology of corticosteroids. Respir Care. 2018; 63 (6): 655–670. doi: 10.4187/respcare.06314.Patel S.K., Saikumar G., Rana J. et al. Dexamethasone: A boon for critically ill COVID-19 patients?. Travel Med Infect Dis. 2020; 37: 101844. doi: 10.1016/j.tmaid.2020.101844.Patel S.K., Saikumar G., Rana J. et al. Dexamethasone: A boon for critically ill COVID-19 patients?. Travel Med Infect Dis. 2020; 37: 101844. doi: 10.1016/j.tmaid.2020.101844.Whitehouse M.W. Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology. 2011; 19 (1): 1–9. doi: 10.1007/s10787-010-0056-2.Whitehouse M.W. Anti-inflammatory glucocorticoid drugs: reflections after 60 years. Inflammopharmacology. 2011; 19 (1): 1–9. doi: 10.1007/s10787-010-0056-2.Iwabuchi K., Yoshie K., Kurakami Y. et al. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases. J Infect Chemother. 2020; 26 (6): 625–632. doi: 10.1016/j.jiac.2020.04.007.Iwabuchi K., Yoshie K., Kurakami Y. et al. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases. J Infect Chemother. 2020; 26 (6): 625–632. doi: 10.1016/j.jiac.2020.04.007.El-Saber Batiha G., Al-Gareeb A.I., Saad H.M., Al-Kuraishy H.M. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022; 30 (4): 1189–1205. doi: 10.1007/s10787-022-00987-z.El-Saber Batiha G., Al-Gareeb A.I., Saad H.M., Al-Kuraishy H.M. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022; 30 (4): 1189–1205. doi: 10.1007/s10787-022-00987-z.Broccoli M.C., Pigoga J.L., Nyirenda M. et al. Essential medicines for emergency care in Africa. Afr J Emerg Med. 2018; 8 (3): 110–117. doi: 10.1016/j.afjem.2018.05.002.Broccoli M.C., Pigoga J.L., Nyirenda M. et al. Essential medicines for emergency care in Africa. Afr J Emerg Med. 2018; 8 (3): 110–117. doi: 10.1016/j.afjem.2018.05.002.Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395 (10223): 473–475. doi: 10.1016/S0140-6736(20)30317-2.Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395 (10223): 473–475. doi: 10.1016/S0140-6736(20)30317-2.Souverein P.C., Berard A., Van Staa T.P. et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004; 90 (8): 859–865. doi: 10.1136/hrt.2003.020180.Souverein P.C., Berard A., Van Staa T.P. et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004; 90 (8): 859–865. doi: 10.1136/hrt.2003.020180.Varas-Lorenzo C., Rodriguez L.A., Maguire A. et al. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007; 192 (2): 376–383. doi: 10.1016/j.atherosclerosis.2006.05.019.Varas-Lorenzo C., Rodriguez L.A., Maguire A. et al. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007; 192 (2): 376–383. doi: 10.1016/j.atherosclerosis.2006.05.019.Sanders B.P., Portman R.J., Ramey R.A. et al. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol. 1992; 89 (4): 816–821. doi: 10.1016/00916749(92)90436-6.Sanders B.P., Portman R.J., Ramey R.A. et al. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol. 1992; 89 (4): 816–821. doi: 10.1016/00916749(92)90436-6.Üsküdar Cansu D., Bodakçi E., Korkmaz C. Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature. Rheumatol Int. 2018; 38 (12): 2337–2343. doi: 10.1007/s00296018-4167-1.Üsküdar Cansu D., Bodakçi E., Korkmaz C. Dose-dependent bradycardia as a rare side effect of corticosteroids: a case report and review of the literature. Rheumatol Int. 2018; 38 (12): 2337–2343. doi: 10.1007/s00296018-4167-1.Kabinger F., Stiller C., Schmitzová J. et al. Mechanism of molnupiravirinduced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology. 2021; 28 (9): 740–746. doi: 10.1038/s41594-021-00651-0.Kabinger F., Stiller C., Schmitzová J. et al. Mechanism of molnupiravirinduced SARS-CoV-2 mutagenesis. Nature Structural & Molecular Biology. 2021; 28 (9): 740–746. doi: 10.1038/s41594-021-00651-0.Mahase E. COVID-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021; 375: n2713. doi: 10.1136/bmj.n2713.Mahase E. COVID-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021; 375: n2713. doi: 10.1136/bmj.n2713.Wen W., Chen C., Tang J. et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022; 54 (1): 516–523. doi: 10.1080/07853890.2022.2034936.Wen W., Chen C., Tang J. et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022; 54 (1): 516–523. doi: 10.1080/07853890.2022.2034936.

The authors declare that there are no conflicts of interest present.